Q-omics provides the consensus-scored GPR158 profile across patient tissues and cancer cell-line models. GPR158 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, GPR158 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GPR158 RNA expression shows 15,925 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, HNSC, and THYM as cancer lineages where GPR158 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR158 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR158 survival associations across molecular data types. GPR158 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR158 RNA expression–survival associations across cancer types. High GPR158 expression shows unfavorable associations in UCEC, KIRP, DLBC and THCA, but favorable associations in LGG and UVM. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for GPR158 RNA expression.
This table summarizes GPR158 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR158. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR158 shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, LIHC, LUSC and BRCA. The HNSC box plot shows higher GPR158 RNA expression in tumor versus normal tissue (log2 FC = +1.126, t-test p < 0.001).
This table shows molecular features associated with GPR158 in patient tissues and cancer cell lines. In patient samples, GPR158 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR158 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
